Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248492 · ClinicalTrials.gov registry record · Phase 2
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
A Phase 2 study, sponsored by Daiichi Sankyo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 253
- Enrollment target
NCT03248492 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 253 participants.
The verdict
NCT03248492, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 253 participants
- Enrollment target
Study Summary
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.
Interventions
- DRUG DS-8201a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2017-08-25 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248492
The ClinicalTrials.gov registry entry for NCT03248492 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-8201a is the first listed.
NCT03248492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03248492 about?
NCT03248492 is a clinical study titled "A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)". Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. Thi...
What is the current status of trial NCT03248492?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 253 participants. The study started on 2017-08-25. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT03248492?
The interventions under investigation include: DS-8201a (DRUG).
Who is sponsoring clinical trial NCT03248492?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.